On April 6, 2022 Medikine, Inc., a privately-held biopharmaceutical company focused on the discovery and development of cytokine mimetics for the treatment of cancer, autoimmune disorders, and infectious diseases, reported that it will deliver a poster presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Medikine, APR 6, 2022, View Source [SID1234611529]). The poster highlights preclinical data on Medikine’s lead program MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikine’s innovative platform technology. PEPTIKINES are cytokine receptor agonists that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presents data on the effects of MDK-703 on CD8, CD4, and memory T-cell populations in human cells in vitro and when administered to non-human primates and CD34-engrafted humanized mice. In addition to increasing the number of CD8 and CD4 T-cells, MDK-703 increased memory T-cells, particularly T memory stem cells (Tscm), a subset of memory lymphocytes endowed with the stem cell-like ability to self-renew, and the multi-potent capacity to reconstitute the entire spectrum of memory and effector subsets.
Dr. Joseph Leveque, President and Chief Medical Officer of Medikine, commented, "I believe that MDK-703 has best-in-class potential as a therapy with the ability to differentiate, maintain, and increase survival of T-cells with critical anti-tumor properties. An additional important feature of MDK-703 is that, as a consequence of its novel structure, it would not be expected to generate neutralizing antibodies to native IL-7, an issue observed with other IL-7-based therapies in clinical development."
Medikine expects MDK-703 to enter first-in-human clinical trials in mid-2022.
Poster Presentation Details
Title: In vitro and in vivo properties of MDK703: An Fc-peptide fusion IL-7Rαγc agonist unrelated in structure to IL-7
Abstract #: 2066
Presenter: Angie Park, PhD, Medikine
Session Title: Immunomodulatory Agents and Interventions 1
Date/Time: Monday, April 11, 2022, from 1:00-5:00 p.m. ET
The poster will be available on the Medikine website at www.Medikine.com following the presentation.